Bei Yang

Statistics

Publications

Citations

138

H-Index

Active since

2013

Affiliations

Exelixis (United States)(Current)

Bei Yang is an author at Exelixis (United States) specializing in pharmacology, population pharmacokinetics, and pharmacokinetics of anticancer drugs.

ORCID

Publications per year

2013–2018

Publications

Population exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma

Steven Lacy, Jace Nielsen, Bei Yang et al. · Cancer Chemotherapy and Pharmacology · 2018 · 51 citations · Full text

Medicine, Oncology, Pharmacology +17

Population PK Analyses of Ubrogepant (MK‐1602), a CGRP Receptor Antagonist: Enriching In‐Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling

Chi‐Chung Li, Marissa F. Dockendorf, Ken Kowalski et al. · The Journal of Clinical Pharmacology · 2017 · 43 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types

Steven Lacy, Bei Yang, Jace Nielsen et al. · Cancer Chemotherapy and Pharmacology · 2018 · 34 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Improved proportional fair scheduling algorithm in LTE uplink with single-user MIMO transmission

Bei Yang, Kai Niu, Zhiqiang He et al. · 2013 · 10 citations

Engineering, Information Technology, Digital Communication +14

1–4 of 4